587 results about "Liver tissue" patented technology

The invention belongs to the technical field of biological medicines, and provides application of DRAM1 as a diagnosis and treatment target for resisting non-alcoholic fatty liver disease related hepatocellular carcinoma in preparation of a kit, a carrier and a medicine aiming at the problem of lack of effective treatment targets of NAFLD-related HCC. As a target spot for resisting the non-alcoholic fatty liver disease related hepatocellular carcinoma, the expression level of the DRAM1 in liver tissues of non-alcoholic fatty liver disease related hepatocellular carcinoma patients and mice is increased. According to the application disclosed by the invention, research is developed aiming at the effect of the DRAM1 in the generation and development of NAFLD-related HCC, the analysis of TCGA liver cancer queue data and a GSE164760 data set is taken as an entry point, the influence of the DRAM1 on the diagnosis and prognosis of the liver cancer is comprehensively analyzed, and verification is carried out through a mouse in-vivo experiment, so that a new thought and a new target spot are provided for clinical diagnosis and treatment of the liver cancer.

The present invention relates to pro-nano-emulsion compositions comprising at least one type of Omega 3 fatty acid capable of converting to nano-emulsion composition having average droplet size of below Ip, typically below 0.5p, and use thereof, particularly as dietary supplement, for preferential delivery of the Omega 3 fatty acid to heart and / or liver tissue of a subject consuming the composition, thereby maintaining normal cardiovascular / hepatic function and / or improving cardiovascular / hepatic disease or disorders.

The invention relates to the technical field of sample preparation and detection, and provides a liver cancer biopsy intraoperative sample preparation and detection device which comprises a device shell, a first protective door and a second protective door are installed on the device shell, a multifunctional processing assembly is installed in the device shell, and an efficient detection assembly is installed in the device shell. A through groove is formed in the device shell in a penetrating mode, a second threaded rod is rotationally connected to the device shell, a mounting frame is in threaded connection to the second threaded rod, a third threaded rod is rotationally connected to the mounting frame, a mounting plate is in threaded connection to the third threaded rod, and a microscope is mounted on the mounting plate. By means of the technical scheme, the problems that in the prior art, a sample preparation detection device cannot automatically and stably dye, clean and dry a plurality of liver tissue slices at the same time, and cannot conveniently and efficiently conduct pathological detection on the liver tissue slices are solved.

The invention relates to the technical field of medical image information processing, discloses an ICG fluorescence image and MRCP three-dimensional model registration fusion display method and system, effectively solves the problems of deep biliary tract structure blurring and form distortion caused by liver tissue scattering effect in intraoperative fluorescence imaging, uses a preoperative model as anatomical prior, and improves the accuracy of the intraoperative fluorescence imaging. A viewpoint correlation optical path depth field is constructed through reverse ray tracing, a spatial variation point spread function is generated accordingly, physical reverse recovery of scattering halo in a fluorescence image is achieved, non-specific background noise such as vascular leakage is effectively inhibited in combination with topological gravitational constraint of a central skeleton, and the detection accuracy is improved. The real pipe diameter and the center line position of the deep bile duct are accurately recovered, non-rigid registration correction is performed on the three-dimensional model based on the recovered high-fidelity image, and projection errors caused by respiratory movement and soft tissue deformation are eliminated.

The invention discloses a serological diagnosis model containing PRO-C3 and application of the serological diagnosis model in preparation of a detection reagent for the fibrosis degree of a CHB patient. The serum combined detection method for PRO-C3, PLT and ALP provided by the invention is a sensitive and efficient method for detecting the fibrosis degree of a CHB patient. Therefore, the PRO-C3 combined with the PLT and the ALP can be used as a novel serological diagnosis model for diagnosing the fibrosis degree of the CHB patient. The serological diagnosis model containing PRO-C3 can be used for preparing a detection reagent and / or a kit for detecting the fibrosis degree of a CHB patient by detecting the fibrosis degree of a quantifiable index liver tissue and sensitively and efficiently detecting the remarkable fibrosis, so that the serological diagnosis model containing PRO-C3 can be used for preparing the detection reagent and / or the kit for detecting the fibrosis degree of the CHB patient.

The invention relates to the technical field of temperature sensors, in particular to a temperature sensor dynamic response acceleration method and system for medical liver testing, and the method comprises the steps: collecting an original temperature measurement sequence outputted by a main temperature sensor in a first target region in real time, synchronously acquiring a reference temperature sequence output by a reference temperature sensor located in a second target area; and based on the physical characteristics of the main temperature sensor and the heat exchange characteristics of the liver tissue, constructing a sensor and liver tissue dynamic response model containing key dynamic parameter vectors. The dynamic response model of the sensor and the liver tissue is constructed, the dynamic characteristics of the sensor and the tissue in the current environment can be accurately quantified, thermal inertia and conduction delay are actively compensated from the algorithm level through the model inverse function, the real-time performance of temperature monitoring is remarkably improved, and the temperature monitoring accuracy is improved. And a timely and reliable feedback signal is provided for closed-loop control.

The invention relates to the technical field of medicines, in particular to a pharmaceutical composition for improving acute alcoholic gastric mucosal lesion and application. The invention discloses the new medical application of the lucid ganoderma, ginseng and kudzuvine root formula for the first time, and experiments and clinical verifications prove that the formula can increase the activity of key enzymes in stomach and liver tissues of a mouse with acute alcoholic gastric mucosal injury, reduce the content of a proinflammatory factor TNF-alpha in the stomach tissues, increase the generation of an anti-inflammatory factor IL-10 in the stomach tissues, relieve the inflammatory injury of ethanol to gastric mucosa, improve the curative effect of alcohol on the gastric mucosa and improve the curative effect of alcohol on the gastric mucosa. The levels of protective factors EGF, SS and PGE-2 in serum are increased, the defense mechanism of gastric mucosa is enhanced, and the repairing capacity of the gastric mucosa is improved. The discovery has great influence on the research and treatment of acute alcoholic gastric mucosal injury diseases, and has clinical practical value.

The invention relates to a liver and gall CT image processing method and system, and relates to the technical field of image processing. According to the liver and gall CT image processing method, a liver and gall CT image is obtained, a liver and gall tissue three-dimensional model is established, and feature recognition analysis is performed to obtain a liver and gall tissue feature data set; carrying out comprehensive analysis to obtain a liver tissue health index and a bile tissue health index; the method comprises the following steps: constructing a complete three-dimensional model of the liver and gall tissues, extracting multi-dimensional features of the liver and gall tissues, performing comprehensive analysis to obtain a comprehensive health index of the liver and gall tissues, performing judgment and analysis on the comprehensive health index and a preset comprehensive health evaluation interval of the liver and gall tissues, and performing health marking on the liver and gall tissues according to a judgment and analysis result. The precision and comprehensiveness of liver and gallbladder health assessment are remarkably improved, nonlinear synthesis is performed on the liver tissue health index and the gallbladder tissue health index obtained through analysis, and the calculated liver and gallbladder tissue comprehensive health index can comprehensively assess the overall health state of the liver and gallbladder system.

The present invention relates to a composition for inducing liver disease in a mammal and a mammal with a liver disease induced using the same. The animal model of the present invention has been found to be an excellent animal model in which fatty liver, hepatic fibrosis, and insulin resistance are evenly induced, and which successfully reproduces the progression of a series of severe liver diseases, from hepatitis and excessive fibrogenesis in liver tissue through tissue hardening (cirrhosis) to liver cancer, and reflects the characteristics of each stage with high reliability. Accordingly, the present invention may be useful as a means for developing a therapeutic agent for chronic liver disease as well as studying the molecular and circulatory mechanisms of each stage of liver disease.

The invention discloses a liver progenitor organoid culture medium and a culture method, and belongs to the technical field of organoid culture. The culture medium comprises a basic culture medium, Jagged-1, Dexamehysone, TGF (Transforming Growth Factor)-alpha, beta-mercaptoethanol, BMP4 (Bone Morphogenetic Protein 4), FGF2 (Fibroblast Growth Factor 2), specific addition factors Glutamax, HEPES (Hydroxyethyl PES), Nicotinamide, Penicillin and the like. The liver progenitor organoid is constructed by using the liver tissue for the first time, continuous growth and efficient proliferation of human liver progenitor cells in vitro can be promoted under the condition that gene editing is not carried out, meanwhile, the pluripotency of the liver progenitor organoid is maintained, and the consistency of specific marker expression is maintained; and a novel batch model is provided for the evaluation of hepatotoxicity at the present stage. From the long-term view, a foundation is laid for constructing a liver organ model with more advanced various differentiated cells.

The invention discloses application of a potential active component 4-methylesculetin of Xiasangju in preparation of a medicine for preventing and treating diabetes, and belongs to the field of medicine. The invention provides an application of 4-methylesculetin in preparation of a medicine for preventing and treating diabetes, which can promote the consumption of glucose by cells, reduce the level of ROS and MDA in liver tissues and increase the level of SOD and GSH-PX in the liver tissues. According to the invention, on the basis of the Xiasangju, the medicinal components of the Xiasangju are researched, the medicinal active components and the administration dosage are defined, the administration safety is improved, and the Xiasangju also plays an important role in preventing and treating diabetic complications.

The invention discloses a preparation method of cordyceps sobolifera polysaccharide and application of the cordyceps sobolifera polysaccharide in relieving acute chemical liver injury. Monosaccharide of the cordyceps sobolifera polysaccharide (abbreviated as CCPW) is composed of glucose, mannose and galactose according to the molar ratio of 8.918: 1: 0.356, and the relative molecular mass is 2.62 * 10 < 4 > Da. Efficacy experiments show that the cordyceps sobolifera homogeneous polysaccharide CCPW can significantly inhibit increase of ALT and AST in a CCl4-induced acute chemical liver injury model mouse, effectively improve the degree of liver cell disruption and swelling, relieve liver inflammatory response, relieve CCl4-induced mouse liver tissue injury, protect mouse intestinal barriers, recover intestinal microbial balance and have obvious liver protection activity. The cordyceps sobolifera polysaccharide CCPW is clear in composition and remarkable in effect, and has wide development and application prospects in the aspect of relieving acute chemical liver injury.

The invention discloses a research method for researching an influence mechanism of high-fat diet on old-age health by using a mouse model, which comprises the following steps: S1, constructing a high-fat diet-induced mouse model: from normal diet feeding of mice to an old mouse stage, dividing the mice into two groups, and respectively performing high-fat diet feeding and normal diet feeding; s2, detecting physiological and functional indexes of the mice in the high-fat diet feeding group and the normal diet feeding group; s3, microbial diversity analysis: performing 16S rRNA sequencing to analyze the community structure of the intestinal microbiota of the mouse; s4, carrying out non-targeted metabonomics analysis: S4.1, carrying out intestinal tract non-targeted metabonomics sequencing; s4.2, carrying out non-targeted metabonomics sequencing on the liver tissues; s5, carrying out transcriptomics analysis; s6, performing conjoint analysis: performing the conjoint analysis on every two results of transcriptomics analysis, non-targeted metabonomics analysis and microbial diversity analysis; and S7, evaluating the influence of the high-fat diet on the health of the old rats by using the data obtained through analysis.

The invention relates to the technical field of molecular biology, gene therapy and drug development, and provides application of TRIM44 as a target in preparation of a drug for treating non-alcoholic fatty liver. The medicine prevents, relieves and / or treats the non-alcoholic fatty liver disease by inhibiting the expression level of TRIM44. According to the application disclosed by the invention, the TRIM44 is taken as a target, and the non-alcoholic fatty liver is prevented, relieved and treated by reducing the expression level of the TRIM44. The TRIM44 inhibitor enables the liver weight and the proportion of the liver in the body weight of a patient to be remarkably reduced, lipid accumulation to be reduced, fat deposition and vacuolation degree of liver tissue to be reduced and liver texture to be improved under poor diet conditions of high fat, high sugar and the like, so that the non-alcoholic fatty liver is prevented, relieved and treated, and the health state of the patient is improved.

The invention provides a construction method and system of a chronic hepatitis B liver tissue inflammation grading prediction model and application. The construction method of the chronic hepatitis B liver tissue inflammation grading prediction model comprises the following steps: S1, screening out a plurality of patients which are diagnosed as chronic hepatitis B through liver tissue biopsy pathology and have clear liver tissue inflammation grading according to inclusion and exclusion standards, and collecting clinical data and serum samples of the patients; s2, performing serum protein N-carbohydrate chain fingerprint spectrum difference analysis on the serum samples of the patients with different ALT levels by adopting an N-carbohydrate fingerprint spectrum technology; s3, on the basis of conventional biochemical indexes and / or N-sugar markers, constructing liver tissue inflammation grading evaluation models under different ALT levels by adopting a binary logistic regression analysis method; and S4, respectively evaluating and selecting the model with the optimal efficiency as a chronic hepatitis B liver tissue inflammation grading prediction model. The chronic hepatitis B liver tissue inflammation grading method can be used for quickly, accurately and noninvasively grading the chronic hepatitis B liver tissue inflammation.

The invention belongs to the field of biotechnology and aquaculture, and particularly relates to a method for improving hypoxia resistance of pelteobagrus vachelli based on hypoxia induction of liver extracellular vesicles of the pelteobagrus vachelli. The method comprises the following steps: extracting high-purity extracellular vesicles EVs in liver tissues of pelteobagrus vachelli subjected to low-oxygen treatment by adopting a method of combining differential centrifugation and high-precision iodixanol density gradient centrifugation; diluting the extracted EVs to 2mu g / mu L by using PBS (Phosphate Buffer Solution) to prepare an EVs suspension; an intraperitoneal injection mode is adopted, the EVs suspension is injected into the body of the pelteobagrus vachelli, and after injection is conducted for 24 hours, the hypoxia resistance of the pelteobagrus vachelli is evaluated through a suffocation point detection test. The invention opens up a brand new path for improving the hypoxia resistance of the pelteobagrus vachelli, provides a new idea and a new method for efficiently enhancing the hypoxia resistance of economic fishes in the field of aquaculture, is expected to play an important role in actual aquaculture production, and assists the sustainable development of the aquaculture industry.

The invention relates to the technical field of healthy food, and discloses a healthy food composition for protecting liver and relieving fatigue and a preparation method of the healthy food composition for protecting liver and relieving fatigue. 5 to 10 parts of propolis; 5-7 parts of a chrysanthemum extract; 2-4 parts of a wolfberry extract; 7-10 parts of a cassia seed extract; 2-5 parts of a ginseng extract; 1.3 to 1.7 parts of a saffron crocus extract; the royal jelly and the propolis are combined according to the formula proportion, the prepared composition finished product has the effect of effectively relieving physical fatigue under the specific dosage, metabolite after exercise can be removed, the composition has the effect of increasing glycogen reserve, and the composition can be used for treating alcoholic liver injury model mice, and has the advantages that the composition finished product can be used for treating alcoholic liver injury; the composition can reduce the content of malondialdehyde and triglyceride in liver tissue and increase the content of glutathione, so that the composition provided by the invention not only has a liver protection effect, but also can relieve physical fatigue, reduce generation of serum urea and lactic acid after exercise and increase in-vivo glycogen reserve.

The present invention relates to novel lipid nanoparticles capable of liver-specific delivery of mRNA, a manufacturing method therefor, and a liver disease therapeutic agent capable of regenerating the liver by liver-specific delivery of the bio-reprogramming factor mRNA using same. The lipid nanoparticles according to the present invention allow for liver-specific delivery of mRNA at very high efficiency, and the lipid nanoparticles that encapsulate the mRNA-based bio-reprogramming factor mRNA are specifically delivered to liver tissues of an individual requiring liver regeneration to induce short-term expression, thereby easily setting the dose and expression period of a therapeutic agent, leading to a significant reduction in side effects of a therapeutic agent for liver regeneration using an existing cell reprogramming factor.

The invention relates to a method for extracting high-purity extracellular vesicles from liver tissues of pelteobagrus vachelli, which comprises the following steps of: firstly, mixing collagenase II and collagenase IV, performing enzymolysis on the tissues, adding a CaCl2 solution, incubating, and digesting the liver tissues into a tissue suspension; then removing cells and fragments through low-speed centrifugation, and filtering to remove impurities by using needle filters of 0.8 [mu] m and 0.22 [mu] m; and finally, further purifying by combining ultracentrifugation with a high-precision iodixanol density gradient centrifugation method, and merging density layers with high purity to obtain high-purity EVs. The method has the characteristics of high extraction purity, high efficiency and simplicity and convenience in operation, and has a wide application prospect.

Provided is a novel Lactobacillus fermentum strain (Accession No. KCTC 14106BP) and a composition for preventing or treating a metabolic disease including the same. A Lactobacillus fermentum according to the present invention may inhibit fat accumulation and increase anti-inflammatory cells in white adipose tissue. In addition, the Lactobacillus fermentum may effectively inhibit fat accumulation in brown adipose tissue and in liver tissue. The Lactobacillus fermentum strain may exhibit excellent blood glucose improvement effect, and in particular, may reduce a fasting blood glucose level. The Lactobacillus fermentum strain may effectively ameliorate insulin resistance by improving glucose tolerance and increasing insulin sensitivity. Therefore, the Lactobacillus fermentum strain may be usefully used to prevent or treat a metabolic disease such as obesity.

The invention relates to the technical field of biological medicine, in particular to radix puerariae and sesame coffee for improving non-alcoholic fatty liver and application of the radix puerariae and sesame coffee. The radix puerariae and sesame coffee comprises the following components in parts by weight: 0.5 part of a fructus cannabis polypeptide solution, 0.5 part of radix puerariae polypeptide solution and 9 parts of coffee. After continuous treatment for 7 weeks, according to liver appearance and liver histopathology observation, it is found that the radix puerariae and sesame coffee mixed liquid effectively reduces lipid deposition and liver fat, and the liver fat lesion is improved. Experimental results show that the radix puerariae and hemp coffee has a remarkable lipid-lowering effect, and can effectively reduce liver fat particles, reduce inflammatory injury, improve liver tissue pathological changes and relieve NAFLD mouse liver tissue injury.

The invention discloses a liver point cloud registration method and device based on a Transform architecture, relates to the technical field of three-dimensional point cloud registration, and aims to solve the problems that mechanical characteristics of various liver tissues and geometric characteristics of point clouds are not comprehensively considered in the process of calculating rigid body and non-rigid body transformation in the existing registration technology, the difference between liver parenchyma and vasculature is ignored, and the registration accuracy is poor. And the registration effect is not good due to the interference of factors such as posture, gravity and pneumoperitoneum pressure. The method comprises the steps of obtaining a first point cloud and a second point cloud, preprocessing the first point cloud through a preset finite element analysis solver and a preset deformation condition to generate a third point cloud, and processing the first point cloud, the second point cloud and the third point cloud in combination with a liver point cloud registration model based on a Transform architecture to generate a liver point cloud registration result. According to the method, different modal features are fused by adopting a Transform architecture suitable for the point cloud, and the potential matching relationship among the modals can be captured, so that the registration effect is improved.

The invention provides a wound sealing and repairing hydrogel patch and a preparation method thereof. The hydrogel patch is provided with an independent adhesion layer and an adhesion layer and anti-adhesion layer combination. The adhesive layer is prepared from gelatin, N-acryloylated amino acid, acrylic acid-N-succinimide ester, 2-hydroxy-4 '-(2-hydroxyethoxy)-2-methyl propiophenone and water through ultraviolet light crosslinking; the anti-adhesion layer is prepared from methacryloyl ethyl sulphobetaine, polyethylene glycol diacrylate, 2-hydroxy-4 '-(2-hydroxyethoxy)-2-methyl propiophenone and water through ultraviolet light crosslinking. The hydrogel patch can be used for sealing and repairing wounds of various tissues (such as skin tissues, liver tissues and stomach tissues), the healing time is shortened, the healing effect is improved, the healing time of a skin incision can be shortened from 14 days to 10 days, the hydrogel patch is superior to other treatment modes according to macroscopic photos and related slices, and the hydrogel patch has a good application prospect. And no-injury healing can be realized.

The present disclosure provides liver-specific Wnt signal enhancing molecules, and related methods of using these molecules to increase Wnt signaling in liver tissues and treat liver diseases and disorders.

The invention belongs to the technical field of biological pharmacy, and provides an application of jonquil glucoside in preparation of a medicine for treating a metabolism-related fatty liver disease, and the application is that the jonquil glucoside is applied to preparation of the medicine for treating the metabolism-related fatty liver disease. The treatment effect of the jonquil glycoside on MASLD is evaluated by adopting a method for establishing a fatty liver model through induction of HFD high-fat, high-fructose and high-cholesterol feed. Results show that the jonquil glucoside can reduce the liver weight by inhibiting weight gain, reduce the content of TC and TG in serum, improve the conditions of liver inflammation and fat change, reduce the oxidative stress level of liver tissue and restore SIRT1 protein expression of the liver tissue to achieve the purpose of treating MASLD.

The present disclosure provides liver-specific Wnt signal enhancing molecules, and related methods of using these molecules to increase Wnt signaling in liver tissues and treat liver diseases and disorders.

The invention belongs to the technical field of biology, and particularly relates to a preparation method of macaca fascicularis liver tissue single-cell suspension. The method comprises the following steps: cleaning macaca fascicularis liver tissues with a pre-cooling buffer solution, and processing into tissue fragments; mixing the tissue fragments with a digestion solution, wherein the digestion solution comprises collagenase I with the final concentration of 1 + / -0.2 mg / ml, collagenase II with the final concentration of 1 + / -0.2 mg / ml, bovine serum albumin with the final concentration of 0.04 + / -0.01% (w / v), DNase I with the final concentration of 10 + / -2 U / ml and the balance of a buffer solution; oscillating and incubating for 30 + / -10min under the conditions of 37 + / -2 DEG C and 150 + / -50rpm, and performing tissue digestion; centrifuging the digested suspension, removing the supernatant, resuspending with a buffer solution, and filtering with a cell sieve to obtain a single-cell primary suspension; and carrying out red blood cell lysis, washing and resuspension on the single-cell primary suspension to prepare the cynomolgus monkey liver tissue single-cell suspension. The method significantly improves the tissue dissociation efficiency, reduces cell adhesion and fragments, effectively protects cell surface antigen epitopes, and has the advantages of simple operation, economy and high efficiency.

The invention relates to an application of beta-nicotinamide mononucleotide (NMN) in prevention and treatment of liver injury caused by aflatoxin B1 (AFB1), the NMN has a good protection effect on the liver injury caused by exposure of the AFB1, and particularly, the serum transaminase activity and liver tissue pathological injury of a mouse using an NMN + AFB1 group are improved compared with those of a mouse in the AFB1 group, and the NMN has a good protection effect on the liver injury caused by exposure of the AFB1 group. Namely, the NMN has a certain protection effect on the mouse liver injury induced by exposure of the AFB1; the content of IL-6, IL-1beta and TNF-alpha in the liver of a mouse in an AFB1 group is remarkably increased, and the expression of IL-6, IL-1beta and TNF-alpha in the liver of the mouse infected with AFB1 is remarkably reduced by the NMN, namely, the NMN relieves the inflammatory response induced by the AFB1. The NMN can effectively relieve the development of mouse AFB1 subchronic poisoning and gradually recover the mouse AFB1 subchronic poisoning to a normal level, so that a new clue and an experimental basis are provided for research and development of an additive or a medicine for resisting AFB1 poisoning.

The invention belongs to the technical field of microorganisms, and particularly relates to a lactobacillus mucus fermentation TY-M26 and application of the lactobacillus mucus fermentation TY-M26, and the preservation number of the lactobacillus mucus fermentation TY-M26 is CGMCC (China General Microbiological Culture Collection Center) No. 32238. The lactobacillus mucilaginosus TY-M26 has high inhibitory activity on alpha-glucosidase activity, and animal experiments prove that the lactobacillus mucilaginosus TY-M26 can significantly relieve diabetes characteristics of mice with type II diabetes, significantly reduce fasting blood-glucose level, significantly improve insulin resistance and serum insulin level, significantly reduce serum Glu level and serum TG level, and can be used for preparing medicines for treating diabetes mellitus. The pathological injury of pancreatic tissues is obviously improved; the lactobacillus mucilaginosus TY-M26 has the advantages that the lactobacillus mucilaginosus TY-M26 can be used for preparing the lactobacillus mucilaginosus TY-M26, the serum ALT level and the serum AST level can be obviously reduced, the pathological injury of liver tissues can be obviously improved, a certain protection effect on the liver is achieved, and the lactobacillus

The invention discloses an application of costunolide in preparation of a medicine for treating and / or preventing a non-alcoholic fatty liver disease. It is found that costunolide can activate an Nrf2-ARE signal channel of a body, liver cell lipid metabolism abnormality is effectively improved from the molecular level, and meanwhile the pathological influence of oxidative damage on liver tissue is remarkably relieved. Experimental data show that the compound has a remarkable intervention effect on NAFLD, a scientific basis is provided for development of a novel liver disease treatment agent due to the unique dual regulation and control mechanism of the compound, particularly, the compound shows an important development prospect in the field of clinical intervention of metabolism-related liver injury, and an innovative solution is provided for NAFLD lacking a special-effect therapy at present.